Tavo Espinoza
CFO
CFO
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Ligand Pharmaceuticals Inc (LGND) | Chief Financial Officer | $522,825 | $4,382,148 |
| 2024 | Ligand Pharmaceuticals Inc (LGND) | Chief Financial Officer | $469,550 | $3,298,556 |
| 2023 | Ligand Pharmaceuticals Inc (LGND) | Chief Financial Officer | $433,005 | $2,450,631 |
| 2022 | Ligand Pharmaceuticals Inc (LGND) | Chief Financial Officer | $330,097 | $3,272,252 |
Earnings-call appearances
-
Ligand Pharmaceuticals Inc Q1 FY2026 Earnings Call2026-05-07
Ligand Pharmaceuticals Inc (LGND)
-
Ligand Pharmaceuticals Inc Q4 FY2025 Earnings Call2026-02-26
Ligand Pharmaceuticals Inc (LGND)
-
Ligand Pharmaceuticals Inc Q3 FY2025 Earnings Call2025-11-06
Ligand Pharmaceuticals Inc (LGND)
-
Ligand Pharmaceuticals Inc Q2 FY2025 Earnings Call2025-08-07
Ligand Pharmaceuticals Inc (LGND)
-
Ligand Pharmaceuticals Inc Q1 FY2025 Earnings Call2025-05-08
Ligand Pharmaceuticals Inc (LGND)
-
Ligand Pharmaceuticals Inc Q4 FY2024 Earnings Call2025-02-27
Ligand Pharmaceuticals Inc (LGND)
-
Ligand Pharmaceuticals Inc Q3 FY2024 Earnings Call2024-11-07
Ligand Pharmaceuticals Inc (LGND)
-
Ligand Pharmaceuticals Inc Q2 FY2024 Earnings Call2024-08-06
Ligand Pharmaceuticals Inc (LGND)
-
Ligand Pharmaceuticals Inc Q4 FY2023 Earnings Call2024-02-27
Ligand Pharmaceuticals Inc (LGND)
-
Ligand Pharmaceuticals Inc Q3 FY2023 Earnings Call2023-11-08
Ligand Pharmaceuticals Inc (LGND)
-
Ligand Pharmaceuticals Inc Q2 FY2023 Earnings Call2023-08-08
Ligand Pharmaceuticals Inc (LGND)
-
Ligand Pharmaceuticals Inc Q1 FY2023 Earnings Call2023-05-04
Ligand Pharmaceuticals Inc (LGND)
-
Ligand Pharmaceuticals Inc Q4 FY2022 Earnings Call2023-02-22
Ligand Pharmaceuticals Inc (LGND)